Efficacy of the novel anxiolytic pregabalin in social anxiety disorder / Atul C. Pande en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 2 (Abril) . - pp. 141-149 Título : Efficacy of the novel anxiolytic pregabalin in social anxiety disorder : A placebo-controlled, multicenter study Tipo de documento: texto impreso Autores: Atul C. Pande, Autor ; Douglas E. Feltner, Autor ; James W. Jefferson, Autor Fecha de publicación: 2023 Artículo en la página: pp. 141-149 Idioma : Inglés (eng) Idioma original : Inglés (eng) Etiquetas: Ansiolíticos, Ansiedad, Pregabalina, Trastornos del comportamiento social, Aumento de peso - efectos de medicamentos. Resumen: Pregabalin is a novel compound in the development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pregabalin 150 mg/d, pregabalin 600 mg/d, or placebo. Link: ./index.php?lvl=notice_display&id=30962 [artículo] Efficacy of the novel anxiolytic pregabalin in social anxiety disorder : A placebo-controlled, multicenter study [texto impreso] / Atul C. Pande, Autor ; Douglas E. Feltner, Autor ; James W. Jefferson, Autor . - 2023 . - pp. 141-149. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 2 (Abril) . - pp. 141-149 Etiquetas: Ansiolíticos, Ansiedad, Pregabalina, Trastornos del comportamiento social, Aumento de peso - efectos de medicamentos. Resumen: Pregabalin is a novel compound in the development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pregabalin 150 mg/d, pregabalin 600 mg/d, or placebo. Link: ./index.php?lvl=notice_display&id=30962

Placebo-controlled study of gabapentin treatment of panic disorder / Atul C. Pande en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 467-471 Título : Placebo-controlled study of gabapentin treatment of panic disorder Tipo de documento: texto impreso Autores: Atul C. Pande, Autor ; Mark H. Pollack, Autor ; Jerri G. Crockatt, Autor Fecha de publicación: 2023 Artículo en la página: pp. 467-471 Idioma : Inglés (eng) Idioma original : Inglés (eng) Etiquetas: Agorafobia, Aminas, Ansiolíticos, Ácidos ciclohexanocarboxílicos, Gabapentina, Trastorno de pánico, Características sexuales. Resumen: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder. One hundred three patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 600 and 3,600 mg/day) or placebo for 8 weeks. Link: ./index.php?lvl=notice_display&id=31183 [artículo] Placebo-controlled study of gabapentin treatment of panic disorder [texto impreso] / Atul C. Pande, Autor ; Mark H. Pollack, Autor ; Jerri G. Crockatt, Autor . - 2023 . - pp. 467-471. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 467-471 Etiquetas: Agorafobia, Aminas, Ansiolíticos, Ácidos ciclohexanocarboxílicos, Gabapentina, Trastorno de pánico, Características sexuales. Resumen: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of panic disorder. One hundred three patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 600 and 3,600 mg/day) or placebo for 8 weeks. Link: ./index.php?lvl=notice_display&id=31183

---

1 (1 - 2 / 2) Por página: 25 50 100 200